首页 > 最新文献

Esophagus最新文献

英文 中文
The impact of time to postoperative recurrence on the prognosis of patients with esophageal cancer post recurrence: exploratory analysis of OGSG 1003. 术后复发时间对复发后食管癌患者预后的影响:OGSG 1003 的探索性分析。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-01 Epub Date: 2024-08-22 DOI: 10.1007/s10388-024-01070-y
Soshi Hori, Makoto Yamasaki, Nobuyuki Yamamoto, Takashi Harino, Kota Momose, Kotaro Yamashita, Koji Tanaka, Keijiro Sugimura, Tomoki Makino, Atsushi Takeno, Osamu Shiraishi, Masaaki Motoori, Hiroshi Miyata, Yutaka Kimura, Motohiro Hirao, Takushi Yasuda, Masahiko Yano, Yuichiro Doki

Background: The association between recurrence timing and prognosis in patients with locally advanced resectable esophageal cancer undergoing neoadjuvant chemotherapy (NAC) followed by esophagectomy remains unclear. This study aimed to clarify this association using multicenter prospective clinical trial data.

Methods: Among 162 patients enrolled in a NAC phase II study comparing the efficacy of cisplatin and fluorouracil plus docetaxel with cisplatin and fluorouracil plus adriamycin, 64 patients with recurrence after R0 resection were included in this study. We evaluated the association between recurrence timing and overall survival after recurrence (OSr), along with clinicopathological factors associated with recurrence timing and OSr.

Results: Among 64 patients, 46 (71.9%) and 59 (92.2%) experienced recurrence within 1 and 2 years after surgery, respectively. Groups based on recurrence timing, including ≤ 6, 6-12, and > 12 months, had median OSr of 3.6, 13.9, and 13.4 months, respectively. The prognosis was significantly poorer for patients with recurrence ≤ 6 months after surgery than for other patients (P < 0.001). Multivariate analysis revealed pathological lymph node staging as an independent factor associated with early recurrence (odds ratio: 3.46, 95% confidence interval: 1.47-8.02, P = 0.0045). On the other hand, multivariate analysis for factors associated with OSr revealed pT (hazard ratio [HR]: 1.91, 95%CI 1.26-2.88, P = 0.0022), early recurrence (HR: 6.88, 95%CI 2.68-17.6, P < 0.001), and treatment after recurrence, with both local treatment (HR: 0.47, 95%CI 0.22-0.98, P = 0.043) and chemotherapy (HR: 0.25, 95%CI 0.11-0.58, P = 0.0011) as independent prognostic factors.

Conclusion: Patients with advanced esophageal cancer experiencing recurrence within 6 months after esophagectomy following NAC have an extremely poor prognosis, suggesting that an advanced pN stage is associated with early recurrence.

背景:接受新辅助化疗(NAC)后再进行食管切除术的局部晚期可切除食管癌患者的复发时间与预后之间的关系仍不清楚。本研究旨在利用多中心前瞻性临床试验数据澄清这种关联:在一项比较顺铂和氟尿嘧啶加多西他赛与顺铂和氟尿嘧啶加阿霉素疗效的新辅助化疗 II 期研究的 162 例患者中,64 例 R0 切除术后复发的患者被纳入本研究。我们评估了复发时间与复发后总生存期(OSr)之间的关系,以及与复发时间和OSr相关的临床病理因素:结果:64 名患者中,分别有 46 人(71.9%)和 59 人(92.2%)在术后 1 年和 2 年内复发。根据复发时间分组,包括≤6个月、6-12个月和>12个月,中位OSr分别为3.6个月、13.9个月和13.4个月。术后≤6个月复发患者的预后明显差于其他患者(P 结论:术后≤6个月复发患者的预后明显差于其他患者:食管切除术后 6 个月内复发的晚期食管癌患者预后极差,这表明晚期 pN 分期与早期复发有关。
{"title":"The impact of time to postoperative recurrence on the prognosis of patients with esophageal cancer post recurrence: exploratory analysis of OGSG 1003.","authors":"Soshi Hori, Makoto Yamasaki, Nobuyuki Yamamoto, Takashi Harino, Kota Momose, Kotaro Yamashita, Koji Tanaka, Keijiro Sugimura, Tomoki Makino, Atsushi Takeno, Osamu Shiraishi, Masaaki Motoori, Hiroshi Miyata, Yutaka Kimura, Motohiro Hirao, Takushi Yasuda, Masahiko Yano, Yuichiro Doki","doi":"10.1007/s10388-024-01070-y","DOIUrl":"10.1007/s10388-024-01070-y","url":null,"abstract":"<p><strong>Background: </strong>The association between recurrence timing and prognosis in patients with locally advanced resectable esophageal cancer undergoing neoadjuvant chemotherapy (NAC) followed by esophagectomy remains unclear. This study aimed to clarify this association using multicenter prospective clinical trial data.</p><p><strong>Methods: </strong>Among 162 patients enrolled in a NAC phase II study comparing the efficacy of cisplatin and fluorouracil plus docetaxel with cisplatin and fluorouracil plus adriamycin, 64 patients with recurrence after R0 resection were included in this study. We evaluated the association between recurrence timing and overall survival after recurrence (OSr), along with clinicopathological factors associated with recurrence timing and OSr.</p><p><strong>Results: </strong>Among 64 patients, 46 (71.9%) and 59 (92.2%) experienced recurrence within 1 and 2 years after surgery, respectively. Groups based on recurrence timing, including ≤ 6, 6-12, and > 12 months, had median OSr of 3.6, 13.9, and 13.4 months, respectively. The prognosis was significantly poorer for patients with recurrence ≤ 6 months after surgery than for other patients (P < 0.001). Multivariate analysis revealed pathological lymph node staging as an independent factor associated with early recurrence (odds ratio: 3.46, 95% confidence interval: 1.47-8.02, P = 0.0045). On the other hand, multivariate analysis for factors associated with OSr revealed pT (hazard ratio [HR]: 1.91, 95%CI 1.26-2.88, P = 0.0022), early recurrence (HR: 6.88, 95%CI 2.68-17.6, P < 0.001), and treatment after recurrence, with both local treatment (HR: 0.47, 95%CI 0.22-0.98, P = 0.043) and chemotherapy (HR: 0.25, 95%CI 0.11-0.58, P = 0.0011) as independent prognostic factors.</p><p><strong>Conclusion: </strong>Patients with advanced esophageal cancer experiencing recurrence within 6 months after esophagectomy following NAC have an extremely poor prognosis, suggesting that an advanced pN stage is associated with early recurrence.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":" ","pages":"472-483"},"PeriodicalIF":2.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Comparison of proton-based Definitive chemoradiotherapy and surgery-based therapy for esophageal squamous cell carcinoma: a multi-center retrospective Japanese cohort study. 更正:基于质子的食管鳞状细胞癌确定性化放疗与手术治疗的比较:日本多中心回顾性队列研究。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-01 DOI: 10.1007/s10388-024-01071-x
Koichi Ogawa, Hitoshi Ishikawa, Takeshi Toyozumi, Kazuhiro Noma, Koji Kono, Hidehiro Hojo, Hiroyasu Tamamura, Yusuke Azami, Toshiki Ishida, Yoshihiro Nabeya, Hiromitsu Iwata, Masayuki Araya, Sunao Tokumaru, Kazushi Maruo, Tatsuya Oda, Hisahiro Matsubara
{"title":"Correction: Comparison of proton-based Definitive chemoradiotherapy and surgery-based therapy for esophageal squamous cell carcinoma: a multi-center retrospective Japanese cohort study.","authors":"Koichi Ogawa, Hitoshi Ishikawa, Takeshi Toyozumi, Kazuhiro Noma, Koji Kono, Hidehiro Hojo, Hiroyasu Tamamura, Yusuke Azami, Toshiki Ishida, Yoshihiro Nabeya, Hiromitsu Iwata, Masayuki Araya, Sunao Tokumaru, Kazushi Maruo, Tatsuya Oda, Hisahiro Matsubara","doi":"10.1007/s10388-024-01071-x","DOIUrl":"10.1007/s10388-024-01071-x","url":null,"abstract":"","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":" ","pages":"495"},"PeriodicalIF":2.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two onset types of achalasia and the long-term course to diagnosis. 贲门失弛缓症的两种发病类型和诊断前的长期病程。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-01 Epub Date: 2024-06-06 DOI: 10.1007/s10388-024-01069-5
Akane Kurosugi, Tomoaki Matsumura, Michiko Sonoda, Tatsuya Kaneko, Satsuki Takahashi, Kenichiro Okimoto, Naoki Akizue, Yuhei Ohyama, Yukiyo Mamiya, Hayato Nakazawa, Ryosuke Horio, Chihiro Goto, Yuki Ohta, Takashi Taida, Atsuko Kikuchi, Mai Fujie, Kentaro Murakami, Masaya Uesato, Yoshihito Ozawa, Jun Kato, Hisahiro Matsubara, Naoya Kato

Background: Recently, the incidence of achalasia has been increasing, but its cause remains unknown. This study aimed to examine the initial symptoms and the course of symptoms and to find new insights into the cause and course of the disease.

Methods: Altogether, 136 patients diagnosed with achalasia by high-resolution manometry (HRM) were enrolled. Questionnaires and chart reviews were conducted to investigate the initial symptoms, time from onset to diagnosis, and comorbidities, as well as the relationship between HRM results, time to diagnosis, and symptom severity.

Results: In total, 67 of 136 patients responded to the questionnaire. The median ages of onset and diagnosis were 42 and 58 years, respectively. The median time from onset to diagnosis was 78.6 months, with 25 cases (37.3%) taking > 10 years to be diagnosed. The symptom onset was gradual and sudden in 52 (77.6%) and 11 (16.4%) patients, respectively. Of the 11 patients with acute onset, three (27.3%) developed anhidrosis at the same time. There was no correlation between the time from onset to diagnosis and esophageal dilatation, resting LES pressure, or mean integrated relaxation pressure (IRP). No correlation was also found between the degree of symptoms and resting LES pressure or IRP.

Conclusion: Esophageal achalasia can have acute or insidious onsets. This finding may help to elucidate the cause of achalasia.

背景:近来,贲门失弛缓症的发病率不断上升,但其病因仍然不明。本研究旨在探讨贲门失弛缓症的初期症状和病程,并对其病因和病程寻找新的见解:方法:共纳入了 136 名通过高分辨率测压(HRM)确诊为贲门失弛缓症的患者。通过问卷调查和病历回顾调查了患者的初始症状、发病到确诊的时间、合并症以及高分辨率测压结果、确诊时间和症状严重程度之间的关系:136名患者中共有67人回答了问卷。发病年龄和确诊年龄的中位数分别为 42 岁和 58 岁。从发病到确诊的中位时间为 78.6 个月,其中 25 例(37.3%)的确诊时间超过 10 年。52名患者(77.6%)和11名患者(16.4%)分别是逐渐和突然发病。在急性发病的 11 名患者中,有 3 人(27.3%)同时出现了多汗症。从发病到确诊的时间与食管扩张、静息 LES 压力或平均综合松弛压力 (IRP) 之间没有相关性。结论:食管贲门失弛缓症的症状程度与静息LES压力或IRP之间也没有相关性:结论:食管贲门失弛缓症可以急性发作,也可以隐匿性发作。结论:食管贲门失弛缓症可以急性发作,也可以隐匿性发作,这一发现可能有助于阐明贲门失弛缓症的病因。
{"title":"Two onset types of achalasia and the long-term course to diagnosis.","authors":"Akane Kurosugi, Tomoaki Matsumura, Michiko Sonoda, Tatsuya Kaneko, Satsuki Takahashi, Kenichiro Okimoto, Naoki Akizue, Yuhei Ohyama, Yukiyo Mamiya, Hayato Nakazawa, Ryosuke Horio, Chihiro Goto, Yuki Ohta, Takashi Taida, Atsuko Kikuchi, Mai Fujie, Kentaro Murakami, Masaya Uesato, Yoshihito Ozawa, Jun Kato, Hisahiro Matsubara, Naoya Kato","doi":"10.1007/s10388-024-01069-5","DOIUrl":"10.1007/s10388-024-01069-5","url":null,"abstract":"<p><strong>Background: </strong>Recently, the incidence of achalasia has been increasing, but its cause remains unknown. This study aimed to examine the initial symptoms and the course of symptoms and to find new insights into the cause and course of the disease.</p><p><strong>Methods: </strong>Altogether, 136 patients diagnosed with achalasia by high-resolution manometry (HRM) were enrolled. Questionnaires and chart reviews were conducted to investigate the initial symptoms, time from onset to diagnosis, and comorbidities, as well as the relationship between HRM results, time to diagnosis, and symptom severity.</p><p><strong>Results: </strong>In total, 67 of 136 patients responded to the questionnaire. The median ages of onset and diagnosis were 42 and 58 years, respectively. The median time from onset to diagnosis was 78.6 months, with 25 cases (37.3%) taking > 10 years to be diagnosed. The symptom onset was gradual and sudden in 52 (77.6%) and 11 (16.4%) patients, respectively. Of the 11 patients with acute onset, three (27.3%) developed anhidrosis at the same time. There was no correlation between the time from onset to diagnosis and esophageal dilatation, resting LES pressure, or mean integrated relaxation pressure (IRP). No correlation was also found between the degree of symptoms and resting LES pressure or IRP.</p><p><strong>Conclusion: </strong>Esophageal achalasia can have acute or insidious onsets. This finding may help to elucidate the cause of achalasia.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":" ","pages":"546-551"},"PeriodicalIF":2.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of taxanes after PD-1 blockade exposure in advanced esophageal squamous cell carcinoma. 晚期食管鳞状细胞癌接触 PD-1 阻断剂后使用紫杉类药物的影响
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-01 Epub Date: 2024-09-02 DOI: 10.1007/s10388-024-01085-5
Kazuhiro Shiraishi, Yuki Takeyasu, Shun Yamamoto, Kotoe Oshima, Hiroshi Imazeki, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Satoru Iwasa, Atsuo Takasima, Ken Kato

Background: Programmed cell death-1 (PD-1) blockade improves survival in patients with advanced esophageal squamous cell carcinoma (ESCC). However, the efficacy of taxanes after exposure to PD-1 blockade remains unclear in patients with advanced ESCC.

Methods: We retrospectively analyzed the clinical outcomes of advanced ESCC patients treated with taxanes (paclitaxel or docetaxel) with/without prior exposure to PD-1 blockade (Exposed /Naïve group) at National Cancer Center Hospital from June 2016 to December 2020.

Results: Ninety-nine patients (Exposed group, n = 32; Naïve group, n = 67) were included. The objective response rate (ORR) of the Exposed group was significantly higher than that of the Naïve group (37.5% vs. 13.4%, p = 0.009). The median progression-free survival was similar between the Exposed and Naïve groups (3.8 vs. 2.8 months, HR 1.12, 95% CI 0.65-1.86, p = 0.66). PD-1 blockade exposure independently predicated higher ORR to taxanes in multivariate analysis. Grade ≥ 3 adverse events were comparable between the Exposed and Naïve groups (45.8% vs. 40.3%, p = 0.64).

Conclusions: Taxanes following PD-1 blockade in advanced ESCC showed a higher ORR but similar PFS compared to taxanes without prior PD-1 exposure.

背景:程序性细胞死亡-1(PD-1)阻断可提高晚期食管鳞状细胞癌(ESCC)患者的生存率。然而,晚期ESCC患者在接受PD-1阻断治疗后使用紫杉类药物的疗效仍不明确:我们回顾性分析了2016年6月至2020年12月期间国立癌症中心医院接受紫杉类药物(紫杉醇或多西他赛)治疗的晚期ESCC患者的临床结果,这些患者之前接受过/未接受过PD-1阻断剂治疗(暴露组/新药组):共纳入99名患者(暴露组,n = 32;新药组,n = 67)。暴露组的客观反应率(ORR)明显高于新药组(37.5% vs. 13.4%,P = 0.009)。暴露组和新药组的中位无进展生存期相似(3.8 个月 vs. 2.8 个月,HR 1.12,95% CI 0.65-1.86,p = 0.66)。在多变量分析中,PD-1阻断剂暴露可独立预测更高的紫杉类药物ORR。暴露组和新药组发生≥3级不良事件的比例相当(45.8% vs. 40.3%,p = 0.64):结论:在晚期ESCC中使用PD-1阻断后的紫杉类药物与未暴露PD-1的紫杉类药物相比,ORR更高,但PFS相似。
{"title":"Impact of taxanes after PD-1 blockade exposure in advanced esophageal squamous cell carcinoma.","authors":"Kazuhiro Shiraishi, Yuki Takeyasu, Shun Yamamoto, Kotoe Oshima, Hiroshi Imazeki, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Satoru Iwasa, Atsuo Takasima, Ken Kato","doi":"10.1007/s10388-024-01085-5","DOIUrl":"10.1007/s10388-024-01085-5","url":null,"abstract":"<p><strong>Background: </strong>Programmed cell death-1 (PD-1) blockade improves survival in patients with advanced esophageal squamous cell carcinoma (ESCC). However, the efficacy of taxanes after exposure to PD-1 blockade remains unclear in patients with advanced ESCC.</p><p><strong>Methods: </strong>We retrospectively analyzed the clinical outcomes of advanced ESCC patients treated with taxanes (paclitaxel or docetaxel) with/without prior exposure to PD-1 blockade (Exposed /Naïve group) at National Cancer Center Hospital from June 2016 to December 2020.</p><p><strong>Results: </strong>Ninety-nine patients (Exposed group, n = 32; Naïve group, n = 67) were included. The objective response rate (ORR) of the Exposed group was significantly higher than that of the Naïve group (37.5% vs. 13.4%, p = 0.009). The median progression-free survival was similar between the Exposed and Naïve groups (3.8 vs. 2.8 months, HR 1.12, 95% CI 0.65-1.86, p = 0.66). PD-1 blockade exposure independently predicated higher ORR to taxanes in multivariate analysis. Grade ≥ 3 adverse events were comparable between the Exposed and Naïve groups (45.8% vs. 40.3%, p = 0.64).</p><p><strong>Conclusions: </strong>Taxanes following PD-1 blockade in advanced ESCC showed a higher ORR but similar PFS compared to taxanes without prior PD-1 exposure.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":" ","pages":"539-545"},"PeriodicalIF":2.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of per-oral endoscopic myotomy in non-achalasia esophageal motility disorders: a systematic review and meta-analysis. 经口内窥镜肌切开术治疗非胆囊炎性食管运动障碍的有效性和安全性:系统回顾和荟萃分析。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-01 Epub Date: 2024-08-14 DOI: 10.1007/s10388-024-01076-6
Rajesh Puri, Suprabhat Giri, Sarat Chandra Panigrahi, Bipadabhanjan Mallick, Preetam Nath, Zubin Dev Sharma, Bimal Kumar Sahu

Per‑oral endoscopic myotomy (POEM) is the preferred endoscopic modality for managing achalasia cardia. However, there are no recommendations on the role of POEM in non‑achalasia esophageal dysmotility disorders (NAEMD), including esophagogastric junction outflow obstruction (EGJOO), distal esophageal spasm (DES), and hypercontractile esophagus (HE). The present systematic review and meta-analysis aimed to assess the safety and efficacy of POEM in the treatment of NAEMD. MEDLINE, Embase, and Scopus were searched from inception to August 2023 for studies analyzing the outcome of POEM in NAEMD. Clinical success and adverse events were the main outcomes assessed. The event rates and their 95% confidence interval were calculated using a random effects model. A total of 11 studies with 271 patients were included in the final analysis. The pooled clinical success rate with POEM in NAEMD was 86.9% (82.9-90.9). On subgroup analysis, the pooled clinical success rates of POEM in DES and EGJOO were 97.8% (90.9-100.0) and 92.7% (86.3-95.1), which were significantly higher than in HE 81.2% (73.5-88.8). Data from limited studies showed that the pooled rate of improvement in dysphagia and chest pain was 88.5% (83.0-93.9) and 87.4% (80.5-94.4). The pooled incidence of overall AEs and serious AEs was 12.6% (5.7-19.5) and 0.3% (0.0-1.9), respectively. On follow-up, the pooled incidence of new-onset heartburn was 18.7% (11.1-26.2). POEM is a safe and efficacious treatment modality for the management of NAEMD with a lower clinical success in patients with HE. Further large-scale studies are required to validate the findings of the present analysis.

口腔内镜下肌切开术(POEM)是治疗贲门失弛缓症的首选内镜方法。然而,对于非贲门失弛缓症食管运动障碍(NAEMD),包括食管胃交界流出道梗阻(EGJOO)、远端食管痉挛(DES)和过度收缩食管(HE),目前还没有关于口腔内镜下肌切开术作用的建议。本系统综述和荟萃分析旨在评估 POEM 治疗非酒精性脑血管病的安全性和有效性。从开始到 2023 年 8 月,在 MEDLINE、Embase 和 Scopus 上检索了分析 POEM 在非酒精性脑血管病中疗效的研究。临床成功率和不良事件是评估的主要结果。采用随机效应模型计算了事件发生率及其 95% 的置信区间。最终分析共纳入了11项研究,271名患者。POEM治疗非酒精性脑血管病的汇总临床成功率为86.9%(82.9-90.9)。在亚组分析中,DES 和 EGJOO POEM 的汇总临床成功率分别为 97.8%(90.9-100.0)和 92.7%(86.3-95.1),明显高于 HE 的 81.2%(73.5-88.8)。有限研究的数据显示,吞咽困难和胸痛的总体改善率分别为 88.5%(83.0-93.9)和 87.4%(80.5-94.4)。总体AE和严重AE的汇总发生率分别为12.6%(5.7-19.5)和0.3%(0.0-1.9)。随访期间,新发胃灼热的总发生率为18.7%(11.1-26.2)。POEM是治疗非酒精性脑血管病的一种安全有效的治疗方式,但在高血压患者中的临床成功率较低。需要进一步开展大规模研究,以验证本分析的结果。
{"title":"Efficacy and safety of per-oral endoscopic myotomy in non-achalasia esophageal motility disorders: a systematic review and meta-analysis.","authors":"Rajesh Puri, Suprabhat Giri, Sarat Chandra Panigrahi, Bipadabhanjan Mallick, Preetam Nath, Zubin Dev Sharma, Bimal Kumar Sahu","doi":"10.1007/s10388-024-01076-6","DOIUrl":"10.1007/s10388-024-01076-6","url":null,"abstract":"<p><p>Per‑oral endoscopic myotomy (POEM) is the preferred endoscopic modality for managing achalasia cardia. However, there are no recommendations on the role of POEM in non‑achalasia esophageal dysmotility disorders (NAEMD), including esophagogastric junction outflow obstruction (EGJOO), distal esophageal spasm (DES), and hypercontractile esophagus (HE). The present systematic review and meta-analysis aimed to assess the safety and efficacy of POEM in the treatment of NAEMD. MEDLINE, Embase, and Scopus were searched from inception to August 2023 for studies analyzing the outcome of POEM in NAEMD. Clinical success and adverse events were the main outcomes assessed. The event rates and their 95% confidence interval were calculated using a random effects model. A total of 11 studies with 271 patients were included in the final analysis. The pooled clinical success rate with POEM in NAEMD was 86.9% (82.9-90.9). On subgroup analysis, the pooled clinical success rates of POEM in DES and EGJOO were 97.8% (90.9-100.0) and 92.7% (86.3-95.1), which were significantly higher than in HE 81.2% (73.5-88.8). Data from limited studies showed that the pooled rate of improvement in dysphagia and chest pain was 88.5% (83.0-93.9) and 87.4% (80.5-94.4). The pooled incidence of overall AEs and serious AEs was 12.6% (5.7-19.5) and 0.3% (0.0-1.9), respectively. On follow-up, the pooled incidence of new-onset heartburn was 18.7% (11.1-26.2). POEM is a safe and efficacious treatment modality for the management of NAEMD with a lower clinical success in patients with HE. Further large-scale studies are required to validate the findings of the present analysis.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":" ","pages":"419-429"},"PeriodicalIF":2.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to chemotherapy could predict the prognosis of esophageal squamous cell carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) followed by surgery: long-term results in a single institute. 化疗反应可预测采用多西他赛、顺铂和氟尿嘧啶(DCF)新辅助治疗后再手术的食管鳞状细胞癌的预后:一家研究所的长期研究结果。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-10 DOI: 10.1007/s10388-024-01062-y
Yasuyoshi Sato, Kazuhiko Mori, Shinichiro Atsumi, Kei Sakamoto, Shuichiro Oya, Asami Okamoto, Masayuki Urabe, Yoshiyuki Miwa, Shoh Yajima, Koichi Yagi, Sachiyo Nomura, Hiroharu Yamashita, Yasuyuki Seto

Background: Preoperative chemotherapy with 5-fluorouracil and cisplatin (FP) followed by surgery has been considered a standard treatment for patients with stage II/III esophageal squamous cell carcinoma (ESCC) based on the results of a phase III trial (JCOG9907) in Japan. Subsequently, the phase III NExT trial (JCOG1109) revealed the survival benefit of the neoadjuvant DCF regimen, which adds docetaxel to FP, and it became a standard treatment. However, the long-term results and prognostic factors of neoadjuvant DCF therapy in the real world are unknown.

Methods: We retrospectively investigated 50 patients with ESCC treated with neoadjuvant DCF therapy from July 2012 to December 2017 at The University of Tokyo Hospital.

Results: Median overall survival (OS) and progression-free survival (PFS) were 32.3 [95% confidence interval (CI) 21.0-NA] and 10.0 months (95% CI 6.3-15.6), respectively. Median OS [not reached (95% CI 31.5-NA) vs. 21.4 months (95% CI 13.5-33.0); p = 0.028] and PFS [83.3 months (95% CI 6.4-NA) vs. 7.4 months (95% CI 6.0-12.8] were significantly longer in patients with an objective response than in non-responders. Of 44 surgical cases, median PFS tended to be longer in pathological lymph node metastasis-negative patients. Conversely, survival did not differ according to cStage (II/III vs. IV) or the average relative dose intensity (ARDI, ≥ 85% vs. < 85%).

Discussion: The response to neoadjuvant DCF therapy could predict patient prognosis. Additionally, pN+ tended to increase the recurrence risk, whereas cStage and ARDI did not influence survival.

背景:根据日本一项III期试验(JCOG9907)的结果,术前使用5-氟尿嘧啶和顺铂(FP)化疗,然后进行手术,一直被认为是II/III期食管鳞状细胞癌(ESCC)患者的标准治疗方法。随后,III 期 NExT 试验(JCOG1109)揭示了在 FP 基础上增加多西他赛的新辅助 DCF 方案的生存获益,并将其作为标准治疗方法。然而,在现实世界中,新辅助 DCF 治疗的长期效果和预后因素尚不清楚:我们回顾性调查了2012年7月至2017年12月在东京大学医院接受新辅助DCF治疗的50例ESCC患者:中位总生存期(OS)和无进展生存期(PFS)分别为32.3个月[95%置信区间(CI)21.0-NA]和10.0个月(95% CI 6.3-15.6)。客观应答患者的中位OS[未达到(95% CI 31.5-NA)vs 21.4个月(95% CI 13.5-33.0);p = 0.028]和PFS[83.3个月(95% CI 6.4-NA)vs 7.4个月(95% CI 6.0-12.8)]明显长于无应答患者。在44例手术病例中,病理淋巴结转移阴性患者的中位生存期往往更长。相反,c分期(II/III期与IV期)或平均相对剂量强度(ARDI,≥85%与≥85%)对生存期没有影响。 讨论:对新辅助DCF治疗的反应可预测患者的预后。此外,pN+往往会增加复发风险,而c分期和ARDI并不影响生存率。
{"title":"Response to chemotherapy could predict the prognosis of esophageal squamous cell carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) followed by surgery: long-term results in a single institute.","authors":"Yasuyoshi Sato, Kazuhiko Mori, Shinichiro Atsumi, Kei Sakamoto, Shuichiro Oya, Asami Okamoto, Masayuki Urabe, Yoshiyuki Miwa, Shoh Yajima, Koichi Yagi, Sachiyo Nomura, Hiroharu Yamashita, Yasuyuki Seto","doi":"10.1007/s10388-024-01062-y","DOIUrl":"10.1007/s10388-024-01062-y","url":null,"abstract":"<p><strong>Background: </strong>Preoperative chemotherapy with 5-fluorouracil and cisplatin (FP) followed by surgery has been considered a standard treatment for patients with stage II/III esophageal squamous cell carcinoma (ESCC) based on the results of a phase III trial (JCOG9907) in Japan. Subsequently, the phase III NExT trial (JCOG1109) revealed the survival benefit of the neoadjuvant DCF regimen, which adds docetaxel to FP, and it became a standard treatment. However, the long-term results and prognostic factors of neoadjuvant DCF therapy in the real world are unknown.</p><p><strong>Methods: </strong>We retrospectively investigated 50 patients with ESCC treated with neoadjuvant DCF therapy from July 2012 to December 2017 at The University of Tokyo Hospital.</p><p><strong>Results: </strong>Median overall survival (OS) and progression-free survival (PFS) were 32.3 [95% confidence interval (CI) 21.0-NA] and 10.0 months (95% CI 6.3-15.6), respectively. Median OS [not reached (95% CI 31.5-NA) vs. 21.4 months (95% CI 13.5-33.0); p = 0.028] and PFS [83.3 months (95% CI 6.4-NA) vs. 7.4 months (95% CI 6.0-12.8] were significantly longer in patients with an objective response than in non-responders. Of 44 surgical cases, median PFS tended to be longer in pathological lymph node metastasis-negative patients. Conversely, survival did not differ according to cStage (II/III vs. IV) or the average relative dose intensity (ARDI, ≥ 85% vs. < 85%).</p><p><strong>Discussion: </strong>The response to neoadjuvant DCF therapy could predict patient prognosis. Additionally, pN+ tended to increase the recurrence risk, whereas cStage and ARDI did not influence survival.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":" ","pages":"514-522"},"PeriodicalIF":2.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Esophagectomy for esophageal cancer in patients with a history of total pharyngolaryngectomy: a Japanese nationwide retrospective cohort study. 一项日本全国性回顾性队列研究:曾接受全咽喉切除术的食管癌患者的食管切除术。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-01 Epub Date: 2024-08-13 DOI: 10.1007/s10388-024-01078-4
Akihiko Okamura, Masayuki Watanabe, Jun Okui, Kengo Kuriyama, Osamu Shiraishi, Takanori Kurogochi, Tetsuya Abe, Hiroshi Sato, Hiroshi Miyata, Yoshihiko Kawaguchi, Yusuke Sato, Hiroaki Nagano, Shinsuke Takeno, Masanobu Nakajima, Kentaro Matsuo, Kentaro Murakami, Katsushi Takebayashi, Sohei Matsumoto, Tomoyuki Okumura, Yoshihiro Kakeji, Koji Kono, Nobuhiko Oridate, Yasushi Toh, Hiroya Takeuchi, Yukio Katori

Background: Second primary esophageal cancer often develops in patients with head and neck cancer, and esophagectomy in patients with a history of total pharyngolaryngectomy (TPL) is challenging. However, the clinical outcomes of these patients have yet to be examined in a multicenter setting.

Methods: We evaluated the surgical outcomes of a nationwide cohort of 62 patients who underwent esophagectomy for esophageal cancer with a history of TPL.

Results: Ivor-Lewis and McKeown esophagectomies were performed in 32 (51.6%) and 30 (48.4%) patients, respectively. Postoperatively, 23 patients (37.1%) developed severe complications, and 7 patients (11.3%) required reoperation within 30 days. Pneumonia and anastomotic leakage occurred in 13 (21.0%) and 16 (25.8%) patients, respectively. Anastomotic leakage occurred more frequently in the McKeown group than in the Ivor-Lewis group (46.7% vs. 6.2%, P < 0.001). The adjusted odds ratio for anastomotic leakage in the McKeown group was 9.64 (95% confidence intervals (CI), 2.11-70.82, P = 0.008). Meanwhile, the 5-year overall survival rates were comparable between the groups (41.8% for Ivor-Lewis and 42.7% for McKeown), and the adjusted hazard ratio of overall survival was 1.44 (95% CI, 0.64-3.29; P = 0.381; Ivor-Lewis as the reference).

Conclusions: In our cohort, anastomotic leakage occurred more frequently after McKeown than Ivor-Lewis esophagectomy, and almost half of patients in the McKeown group experienced leakage. Ivor-Lewis esophagectomy is preferred for decreasing anastomotic leakage when oncologically and technically feasible.

背景:第二原发性食管癌常发生在头颈部癌症患者身上,而对有全咽喉切除术(TPL)病史的患者进行食管切除术具有挑战性。然而,这些患者的临床疗效尚未在多中心环境中进行研究:我们评估了全国范围内 62 例因食管癌接受食管切除术且有 TPL 病史的患者的手术效果:分别有 32 名(51.6%)和 30 名(48.4%)患者接受了 Ivor-Lewis 和 McKeown 食管切除术。术后,23 名患者(37.1%)出现严重并发症,7 名患者(11.3%)需要在 30 天内再次手术。肺炎和吻合口漏分别发生在 13 例(21.0%)和 16 例(25.8%)患者身上。麦考恩组的吻合口漏发生率高于艾弗-刘易斯组(46.7% 对 6.2%,P 结论:麦考恩组的吻合口漏发生率高于艾弗-刘易斯组:在我们的队列中,McKeown 食管切除术后吻合口漏的发生率高于 Ivor-Lewis 食管切除术,McKeown 组中几乎一半的患者都出现了吻合口漏。在肿瘤学和技术上可行的情况下,伊沃-刘易斯食管切除术是减少吻合口漏的首选。
{"title":"Esophagectomy for esophageal cancer in patients with a history of total pharyngolaryngectomy: a Japanese nationwide retrospective cohort study.","authors":"Akihiko Okamura, Masayuki Watanabe, Jun Okui, Kengo Kuriyama, Osamu Shiraishi, Takanori Kurogochi, Tetsuya Abe, Hiroshi Sato, Hiroshi Miyata, Yoshihiko Kawaguchi, Yusuke Sato, Hiroaki Nagano, Shinsuke Takeno, Masanobu Nakajima, Kentaro Matsuo, Kentaro Murakami, Katsushi Takebayashi, Sohei Matsumoto, Tomoyuki Okumura, Yoshihiro Kakeji, Koji Kono, Nobuhiko Oridate, Yasushi Toh, Hiroya Takeuchi, Yukio Katori","doi":"10.1007/s10388-024-01078-4","DOIUrl":"10.1007/s10388-024-01078-4","url":null,"abstract":"<p><strong>Background: </strong>Second primary esophageal cancer often develops in patients with head and neck cancer, and esophagectomy in patients with a history of total pharyngolaryngectomy (TPL) is challenging. However, the clinical outcomes of these patients have yet to be examined in a multicenter setting.</p><p><strong>Methods: </strong>We evaluated the surgical outcomes of a nationwide cohort of 62 patients who underwent esophagectomy for esophageal cancer with a history of TPL.</p><p><strong>Results: </strong>Ivor-Lewis and McKeown esophagectomies were performed in 32 (51.6%) and 30 (48.4%) patients, respectively. Postoperatively, 23 patients (37.1%) developed severe complications, and 7 patients (11.3%) required reoperation within 30 days. Pneumonia and anastomotic leakage occurred in 13 (21.0%) and 16 (25.8%) patients, respectively. Anastomotic leakage occurred more frequently in the McKeown group than in the Ivor-Lewis group (46.7% vs. 6.2%, P < 0.001). The adjusted odds ratio for anastomotic leakage in the McKeown group was 9.64 (95% confidence intervals (CI), 2.11-70.82, P = 0.008). Meanwhile, the 5-year overall survival rates were comparable between the groups (41.8% for Ivor-Lewis and 42.7% for McKeown), and the adjusted hazard ratio of overall survival was 1.44 (95% CI, 0.64-3.29; P = 0.381; Ivor-Lewis as the reference).</p><p><strong>Conclusions: </strong>In our cohort, anastomotic leakage occurred more frequently after McKeown than Ivor-Lewis esophagectomy, and almost half of patients in the McKeown group experienced leakage. Ivor-Lewis esophagectomy is preferred for decreasing anastomotic leakage when oncologically and technically feasible.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":" ","pages":"438-446"},"PeriodicalIF":2.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of cases for which esophageal endoscopic submucosal dissection under general anesthesia is recommended 建议在全身麻醉下进行食管内镜黏膜下剥离术的病例特征
IF 2.4 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-17 DOI: 10.1007/s10388-024-01086-4
Atsushi Goto, Koichi Hamabe, Shunsuke Ito, Shinichi Hashimoto, Jun Nishikawa, Taro Takami

Background/aims

Esophageal endoscopic submucosal dissection (ESD) performed under general anesthesia can potentially provide more stable treatment in difficult cases than that under sedation. We evaluated the clinical characteristics and outcomes of ESD performed under general anesthesia compared with those under propofol sedation and discussed the cases in which general anesthesia is recommended.

Patients and methods

In total, 292 lesions in 265 consecutive patients undergoing esophageal ESD at Yamaguchi University Hospital from 2013 to 2023 were included in this retrospective study.

Results

ESD was performed under general anesthesia for 92 lesions in 81 patients and under propofol sedation for 200 lesions in 184 patients. Tumor long-axis diameter was larger (39.8 ± 14.4 mm vs. 32.4 ± 9.9 mm, p < 0.01) and dissection speed was faster (10.5 ± 5.9 mm2/min vs. 7.5 ± 4.2 mm2/min, p < 0.01) in the general anesthesia group versus the sedation group. In the sedation group, a treatment history of pharyngeal cancer was significantly associated with a slower dissection speed (p = 0.037). The sedation group showed higher frequencies of hypoxemia (0% vs 9.8%, p < 0.01), interruption due to body movement (0% vs 13%, p < 0.01), and acute adverse events (21.7% vs 33.5%, p = 0.05). A treatment history of pharyngeal cancer was shown to be the significant factor contributing to acute adverse events (p = 0.018).

Conclusion

Esophageal ESD under general anesthesia can be a treatment option in patients with difficulty in performing stable procedures with propofol sedation. Especially in patients with a treatment history of pharyngeal cancer in whom ESD is more difficult to be performed and who are at higher risk for acute adverse events, general anesthesia can be considered.

背景/目的与镇静相比,在全身麻醉下进行食管内镜黏膜下剥离术(ESD)可能为疑难病例提供更稳定的治疗。我们评估了与异丙酚镇静下相比,全身麻醉下进行的ESD的临床特征和结果,并讨论了推荐使用全身麻醉的病例。结果81例患者的92个病灶在全身麻醉下进行了ESD,184例患者的200个病灶在异丙酚镇静下进行了ESD。全身麻醉组与镇静组相比,肿瘤长轴直径更大(39.8 ± 14.4 mm vs. 32.4 ± 9.9 mm,p < 0.01),解剖速度更快(10.5 ± 5.9 mm2/min vs. 7.5 ± 4.2 mm2/min,p < 0.01)。在镇静组中,咽癌治疗史与较慢的解剖速度显著相关(p = 0.037)。镇静组出现低氧血症(0% vs 9.8%,p < 0.01)、因身体移动而中断手术(0% vs 13%,p < 0.01)和急性不良事件(21.7% vs 33.5%,p = 0.05)的频率较高。咽癌治疗史是导致急性不良事件的重要因素(p = 0.018)。结论对于难以在异丙酚镇静下进行稳定手术的患者来说,全身麻醉下食管ESD是一种治疗选择。特别是对于有咽癌治疗史的患者,ESD 更难在他们身上实施,而且他们发生急性不良事件的风险更高,因此可以考虑全身麻醉。
{"title":"Characteristics of cases for which esophageal endoscopic submucosal dissection under general anesthesia is recommended","authors":"Atsushi Goto, Koichi Hamabe, Shunsuke Ito, Shinichi Hashimoto, Jun Nishikawa, Taro Takami","doi":"10.1007/s10388-024-01086-4","DOIUrl":"https://doi.org/10.1007/s10388-024-01086-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background/aims</h3><p>Esophageal endoscopic submucosal dissection (ESD) performed under general anesthesia can potentially provide more stable treatment in difficult cases than that under sedation. We evaluated the clinical characteristics and outcomes of ESD performed under general anesthesia compared with those under propofol sedation and discussed the cases in which general anesthesia is recommended.</p><h3 data-test=\"abstract-sub-heading\">Patients and methods</h3><p>In total, 292 lesions in 265 consecutive patients undergoing esophageal ESD at Yamaguchi University Hospital from 2013 to 2023 were included in this retrospective study.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>ESD was performed under general anesthesia for 92 lesions in 81 patients and under propofol sedation for 200 lesions in 184 patients. Tumor long-axis diameter was larger (39.8 ± 14.4 mm vs. 32.4 ± 9.9 mm, <i>p</i> &lt; 0.01) and dissection speed was faster (10.5 ± 5.9 mm<sup>2</sup>/min vs. 7.5 ± 4.2 mm<sup>2</sup>/min, <i>p</i> &lt; 0.01) in the general anesthesia group versus the sedation group. In the sedation group, a treatment history of pharyngeal cancer was significantly associated with a slower dissection speed (<i>p</i> = 0.037). The sedation group showed higher frequencies of hypoxemia (0% vs 9.8%, <i>p</i> &lt; 0.01), interruption due to body movement (0% vs 13%, <i>p</i> &lt; 0.01), and acute adverse events (21.7% vs 33.5%, <i>p</i> = 0.05). A treatment history of pharyngeal cancer was shown to be the significant factor contributing to acute adverse events (<i>p</i> = 0.018).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Esophageal ESD under general anesthesia can be a treatment option in patients with difficulty in performing stable procedures with propofol sedation. Especially in patients with a treatment history of pharyngeal cancer in whom ESD is more difficult to be performed and who are at higher risk for acute adverse events, general anesthesia can be considered.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":"42 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The totally mechanical Collard technique for cervical esophagogastric anastomosis reduces anastomotic stricture compared with triangular anastomosis in minimally invasive esophagectomy with gastric conduit reconstruction through the retrosternal route: a propensity score-matched study 在通过胸骨后途径进行胃导管重建的微创食管切除术中,与三角吻合术相比,完全机械化的 Collard 颈食管胃吻合术可减少吻合口狭窄:一项倾向评分匹配研究
IF 2.4 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-13 DOI: 10.1007/s10388-024-01088-2
Hironobu Goto, Taro Oshikiri, Yasufumi Koterazawa, Ryuichiro Sawada, Taro Ikeda, Hitoshi Harada, Naoki Urakawa, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Yoshihiro Kakeji

Background

Cervical esophagogastric anastomosis is conventionally performed using the McKeown esophagectomy. However, an optimal anastomotic technique has not yet been established. This study aimed to compare the clinical outcomes of triangular anastomosis (TA) and totally mechanical Collard anastomosis (TMCA) for cervical esophagogastric anastomosis during minimally invasive esophagectomy with gastric conduit reconstruction through the retrosternal route.

Methods

In this matched- cohort study, 117 patients who underwent minimally invasive esophagectomy between 2019 and 2024 were divided into TA and TMCA groups. The TA technique was performed between September 2019 and December 2021, and the TMCA technique was performed between January 2022 and January 2024. We then compared the surgical outcomes and postoperative complications (pneumonia, recurrent laryngeal nerve palsy, anastomotic leakage, and stricture) between the two groups.

Results

Propensity score matching revealed that 40 patients were included in both the TA and TMCA groups. The rates of pneumonia, recurrent laryngeal nerve palsy, and anastomotic leakage were not significantly different between the two groups. However, the rate of anastomotic stricture was lower in the TMCA than in the TA group (2.5% vs. 27.5%, respectively, P = 0.003).

Conclusions

Compared with the TA technique, the TMCA technique reduced the rate of anastomotic stricture when performing cervical esophagogastric anastomosis during minimally invasive esophagectomy with gastric conduit reconstruction through the retrosternal route.

背景传统上采用麦氏食管切除术进行颈食管胃吻合术。然而,最佳的吻合技术尚未确立。本研究旨在比较三角吻合术(TA)和完全机械科拉德吻合术(TMCA)在微创食管切除术中通过胸骨后途径进行胃导管重建的颈食管胃吻合术的临床效果。方法在这项匹配队列研究中,117 名在 2019 年至 2024 年期间接受微创食管切除术的患者被分为 TA 组和 TMCA 组。TA技术在2019年9月至2021年12月期间进行,TMCA技术在2022年1月至2024年1月期间进行。然后,我们比较了两组患者的手术效果和术后并发症(肺炎、喉返神经麻痹、吻合口漏和狭窄)。两组患者的肺炎、喉返神经麻痹和吻合口漏发生率无明显差异。结论与 TA 技术相比,TMCA 技术降低了经胸骨后途径进行微创食管切除术和胃导管重建术中颈食管胃吻合术的吻合口狭窄率。
{"title":"The totally mechanical Collard technique for cervical esophagogastric anastomosis reduces anastomotic stricture compared with triangular anastomosis in minimally invasive esophagectomy with gastric conduit reconstruction through the retrosternal route: a propensity score-matched study","authors":"Hironobu Goto, Taro Oshikiri, Yasufumi Koterazawa, Ryuichiro Sawada, Taro Ikeda, Hitoshi Harada, Naoki Urakawa, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Yoshihiro Kakeji","doi":"10.1007/s10388-024-01088-2","DOIUrl":"https://doi.org/10.1007/s10388-024-01088-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Cervical esophagogastric anastomosis is conventionally performed using the McKeown esophagectomy. However, an optimal anastomotic technique has not yet been established. This study aimed to compare the clinical outcomes of triangular anastomosis (TA) and totally mechanical Collard anastomosis (TMCA) for cervical esophagogastric anastomosis during minimally invasive esophagectomy with gastric conduit reconstruction through the retrosternal route.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>In this matched- cohort study, 117 patients who underwent minimally invasive esophagectomy between 2019 and 2024 were divided into TA and TMCA groups. The TA technique was performed between September 2019 and December 2021, and the TMCA technique was performed between January 2022 and January 2024. We then compared the surgical outcomes and postoperative complications (pneumonia, recurrent laryngeal nerve palsy, anastomotic leakage, and stricture) between the two groups.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Propensity score matching revealed that 40 patients were included in both the TA and TMCA groups. The rates of pneumonia, recurrent laryngeal nerve palsy, and anastomotic leakage were not significantly different between the two groups. However, the rate of anastomotic stricture was lower in the TMCA than in the TA group (2.5% vs. 27.5%, respectively, <i>P</i> = 0.003).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Compared with the TA technique, the TMCA technique reduced the rate of anastomotic stricture when performing cervical esophagogastric anastomosis during minimally invasive esophagectomy with gastric conduit reconstruction through the retrosternal route.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":"209 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repeat endoscopic submucosal dissection close to the initial endoscopic submucosal dissection scar for superficial esophageal squamous cell carcinoma 针对浅表食管鳞状细胞癌,在首次内镜黏膜下剥离术疤痕附近再次进行内镜黏膜下剥离术
IF 2.4 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-27 DOI: 10.1007/s10388-024-01074-8
Koki Matsuoka, Tsukasa Ishida, Tetsuya Yoshizaki, Yoshinobu Yamamoto, Mineo Iwatate, Yasuaki Kitamura, Tomoya Sako, Atsushi Ikeda, Takayuki Ose, Fumiaki Kawara, Ryusuke Ariyoshi, Yasushi Sano, Hirofumi Abe, Shinwa Tanaka, Toshitatsu Takao, Yoshinori Morita, Takashi Toyonaga, Toshio Shimokawa, Yuzo Kodama

Background

Repeat endoscopic submucosal dissection for metachronous recurrence of esophageal squamous cell carcinoma close to previous endoscopic submucosal dissection scars is challenging. Therefore, this study evaluated the efficacy and safety of repeat endoscopic submucosal dissection for recurrent esophageal squamous cell carcinoma.

Methods

The study included 1680 patients. After propensity score matching, esophageal endoscopic submucosal dissection-related outcomes were compared between the post-endoscopic submucosal dissection scar group (n = 91) and first endoscopic submucosal dissection group (n = 910). The Kaplan–Meier method and log-rank tests were used to compare both groups’ survival and local recurrence curves.

Results

After propensity score matching, the two groups showed no significant difference in en bloc resection rate (97.80% vs. 99.56%, p = 0.096), treatment time (64.75 min vs 61.33 min, p = 0.448), recurrence rate (3.30% vs. 2.20%, p = 0.458), and stricture rate (7.69% vs. 4.07%, p = 0.110). However, the perforation rate was higher in the post-endoscopic submucosal dissection scar group than in the first endoscopic submucosal dissection group (4.40% vs. 1.10%, p = 0.031). The 5-year overall survival rates in the post-endoscopic submucosal dissection scar and first endoscopic submucosal dissection groups were 88.6% and 89.0%, respectively.

Conclusions

Repeated esophageal endoscopic submucosal dissection for recurrent esophageal squamous cell carcinoma yielded satisfactory clinical outcomes and survival rates. Therefore, repeat endoscopic submucosal dissection may effectively treat esophageal squamous cell carcinoma recurrence close to the initial endoscopic submucosal dissection scars.

背景重复内镜黏膜下剥离术治疗食管鳞状细胞癌的近端复发具有挑战性。因此,本研究评估了重复内镜黏膜下剥离术治疗复发性食管鳞状细胞癌的有效性和安全性。经过倾向评分匹配后,比较了内镜粘膜下剥离术后瘢痕组(n = 91)和首次内镜粘膜下剥离术组(n = 910)的食管内镜粘膜下剥离术相关结果。采用卡普兰-梅耶法和对数秩检验比较两组患者的生存率和局部复发率曲线。80% vs. 99.56%,p = 0.096)、治疗时间(64.75 分钟 vs. 61.33 分钟,p = 0.448)、复发率(3.30% vs. 2.20%,p = 0.458)和狭窄率(7.69% vs. 4.07%,p = 0.110)无明显差异。然而,内镜粘膜下剥离术后疤痕组的穿孔率高于首次内镜粘膜下剥离术组(4.40% 对 1.10%,P = 0.031)。内镜下粘膜下剥离术后瘢痕组和首次内镜下粘膜下剥离术后瘢痕组的 5 年总生存率分别为 88.6% 和 89.0%。因此,重复内镜黏膜下剥离术可有效治疗靠近首次内镜黏膜下剥离术疤痕的食管鳞癌复发。
{"title":"Repeat endoscopic submucosal dissection close to the initial endoscopic submucosal dissection scar for superficial esophageal squamous cell carcinoma","authors":"Koki Matsuoka, Tsukasa Ishida, Tetsuya Yoshizaki, Yoshinobu Yamamoto, Mineo Iwatate, Yasuaki Kitamura, Tomoya Sako, Atsushi Ikeda, Takayuki Ose, Fumiaki Kawara, Ryusuke Ariyoshi, Yasushi Sano, Hirofumi Abe, Shinwa Tanaka, Toshitatsu Takao, Yoshinori Morita, Takashi Toyonaga, Toshio Shimokawa, Yuzo Kodama","doi":"10.1007/s10388-024-01074-8","DOIUrl":"https://doi.org/10.1007/s10388-024-01074-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Repeat endoscopic submucosal dissection for metachronous recurrence of esophageal squamous cell carcinoma close to previous endoscopic submucosal dissection scars is challenging. Therefore, this study evaluated the efficacy and safety of repeat endoscopic submucosal dissection for recurrent esophageal squamous cell carcinoma.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The study included 1680 patients. After propensity score matching, esophageal endoscopic submucosal dissection-related outcomes were compared between the post-endoscopic submucosal dissection scar group (n = 91) and first endoscopic submucosal dissection group (n = 910). The Kaplan–Meier method and log-rank tests were used to compare both groups’ survival and local recurrence curves.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>After propensity score matching, the two groups showed no significant difference in <i>en bloc</i> resection rate (97.80% vs. 99.56%, <i>p</i> = 0.096), treatment time (64.75 min vs 61.33 min, <i>p</i> = 0.448), recurrence rate (3.30% vs. 2.20%, <i>p</i> = 0.458), and stricture rate (7.69% vs. 4.07%, <i>p</i> = 0.110). However, the perforation rate was higher in the post-endoscopic submucosal dissection scar group than in the first endoscopic submucosal dissection group (4.40% vs. 1.10%, <i>p</i> = 0.031). The 5-year overall survival rates in the post-endoscopic submucosal dissection scar and first endoscopic submucosal dissection groups were 88.6% and 89.0%, respectively.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Repeated esophageal endoscopic submucosal dissection for recurrent esophageal squamous cell carcinoma yielded satisfactory clinical outcomes and survival rates. Therefore, repeat endoscopic submucosal dissection may effectively treat esophageal squamous cell carcinoma recurrence close to the initial endoscopic submucosal dissection scars.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":"25 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141770559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Esophagus
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1